CRISPR Therapeutics AG

Market cap: $5,973,490,087

Exchange: NAS

Sector: Health Technology

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

STOCK PRICE CHART

Key Statistics

Company Name

CRISPR Therapeutics AG

Average Volume (10 days)

1,523,403

Average Volume (30 days)

2,003,130

Moving Average (50 days)

$71.1

Moving Average (200 days)

$62.48

Ex-Divided Date

n/a

Dividend Yield

0

P/E Ratio

19.1699

Market Cap

5,973,490,087

Shares Outstanding

77,457,081

52-Week High Split Adjust Only

142.64

52-Week Low Split Adjust Only

42.51

Employee Count

410

Beta

1.5752

Next Earnings Date

2022-07-28

TTM Dividend Rate Per Share

0

Price Changes

Past 5 days

-0.08%

Past 30 days

0.15%

Past 3 months

0.46%

Past 6 months

0.25%

Past year

-0.35%

Past 2 years

-0.15%

Past 5 years

3.35%

Max % Change

4.47%

PEER GROUP COMPARATIVE PERFORMANCE

NameTickerPrice/Sales (ttm)Price/Book (ttm)Forward P/EPEG RatioEV/Revenue
CRISPR Therapeutics AGCRSP8132.954.96-144.88132.956492.43
Peer AvgN/An/an/a-0.7n/an/a
Oyster Point Pharma IncOYSTn/an/a-4.9n/an/a
Ovid Therapeutics IncOVIDn/an/a2.0n/an/a